MR Solutions, the pioneer and leading supplier in cryogen-free superconducting MRI up to 7.0T, has been chosen by the IMAPPI consortium among the historical partners to complete the project replacing the previously selected partner. The IMAPPI project is supported by a French Government grant managed by the French National Research Agency (ANR) under the program “Investissements d’Avenir” (with reference ANR- 10-EQPX-05-01/IMAPPI Equipex).
In March 2016, MR Solutions installed phase 2 of the IMAPPI project which consists of an in-line PET module with a high field MRI system where the data are acquired sequentially and co-registered together automatically.
The final phase of the project, phase 3, will consist of a large bore high field MRI with a PET module inserted in the field of view of the MRI for simultaneously acquiring PET and MR data. The simultaneous PET/MR system will be installed before fall 2016. Both phase 2 and phase 3 systems are designed for the imaging of rodents. MR Solutions is one of the most innovative companies in recent years in the MRI area, and today with its PET modules, the company can demonstrate its full capabilities in multimodality imaging.
According to Dr François Brunotte, project coordinator and Professor of nuclear medicine, “we truly believe that multi-parametric and quantitative images from the IMAPPI PET/MR imager will bring crucial advantages in oncology and cardiovascular research due to its high soft tissue contrast and high resolution. Beside the expertise brought by MR Solutions, the project takes advantage from the close presence of hospitals, labs and companies in various fields such as physics, chemistry, biology, medical imaging. The installation of the imager in the department of Nuclear Medicine at the Centre Georges-François Leclerc-CGFL, specialising in oncology makes easy an efficient translation from bench to the clinic.”
Dr David Taylor, Chairman and CEO of MR Solutions Ltd explains: “we are extremely delighted to be the company that will complete the IMAPPI project. Only a company with strong expertise in MRI, as MR Solutions, can achieve the integration of a PET scanner with a high field MR system. MR Solutions has been investing massively in the multi-modality area with an innovative approach and we are pleased to become the key player in the IMAPPI project.”
Since the IMAPPI project has started, MR Solutions has been a reliable partner. “The company has demonstrated strong means and capabilities to achieve smoothly the Phase 3” states Mr Jean-Jacques Wawrzyniak, Directeur General of the Fondation de Cooperation Scientifique (FCS) Bourgogne Franche-comté, the coordinating IMAPPI project partner.
Fabrice Chaumard, VP Sales and Marketing at MR Solutions Ltd, adds “as one of the initiators of the IMAPPI project, I’m glad to have MR Solutions as the leading partners and to work again in close collaboration with the all the partners in Dijon. This project, binding two modalities, PET and high-field MRI generates a huge amount of interest in the research community looking at translational imaging to the clinic. MR Solutions brings its expertise from the preclinical area but also from the clinical area.”
About MR Solutions:
MR Solutions, Guildford, Surrey, UK, has over 30 years’ experience and in excess of 1000 installations across the world. Its scanners are renowned for their excellence in terms of superior soft tissue contrast and molecular imaging ability. Operating out of offices in the UK, USA and with distributors in all the major markets, maintenance and service coverage is offered across the globe. MR Solutions has its global headquarters at Ashbourne House, The Guildway, Old Portsmouth Road, Guildford, Surrey GU3 1LR.
